EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer

Gaku Yamamoto, Kosuke Tanaka, Ryo Kamata, Hitoshi Saito, Tomoko Yamamori-Morita, Takehiro Nakao, Jie Liu, Shunta Mori, Shigehiro Yagishita, Akinobu Hamada, Yuki Shinno, Tatsuya Yoshida und 8 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Gaku Yamamoto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Collaborative Research and Developments, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan; D…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cell Cycle Proteins, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRASG12C inhibitors sotorasib and adagrasib have been approved for the treatment of KRASG12C-mutant non-small cell lung cancer (NSCLC). However, the efficacy of single-agent treatments is limited, presumably due to multiple resistance mechanisms. To overcome these therapeutic limitations, combination strategies that potentiate the antitumor efficacy of KRASG12C inhibitors must be developed. Through unbiased high-throughput screening of 1395 kinase inhibitors, we identified adavosertib, a WEE1 inhibitor, as a promising combination partner of sotorasib. The combination of sotorasib and adavosertib exhibited synergistic antiproliferative activities both in vitro and in vivo, irrespective of TP53, STK11, and KEAP1 co-mutation profiles. WEE1 inhibition potentiated MCL-1-mediated apoptosis in sotorasib-treated cancer cells. Mechanistically, the combination downregulated MCL-1 protein levels by attenuating de novo translation and enhancing its degradation. WEE1 overexpression conferred resistance against sotorasib via MCL-1 upregulation. Moreover, cells that acquired sotorasib resistance profoundly upregulated both WEE1 and MCL-1 proteins, highlighting WEE1 as a crucial driver of sotorasib resistance. Importantly, WEE1 inhibition re-sensitized resistant cells to sotorasib treatment. The current findings demonstrate that combined inhibition of KRASG12C and WEE1 not only exhibits synergistic antitumor efficacy but also overcomes resistance to KRASG12C inhibitors, thus representing a novel therapeutic strategy for KRASG12C-mutant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCell Cycle ProteinsDrug Resistance, NeoplasmLung NeoplasmsProtein-Tyrosine KinasesProto-Oncogene Proteins p21(ras)Protein Kinase InhibitorsHumansAnimalsMyeloid Cell Leukemia Sequence 1 ProteinPyrimidinesCell Line, TumorMiceApoptosisXenograft Model Antitumor AssaysPyrazolesMutationCell ProliferationNuclear ProteinsDrug SynergismPyrimidinones

Stichwörter der Autor:innen

AdavosertibApoptosisCombination therapyDrug resistanceMCL-1Sotorasib

Substanzen

WEE1 protein, humanCell Cycle ProteinsProtein-Tyrosine KinasesMyeloid Cell Leukemia Sequence 1 ProteinadavosertibProto-Oncogene Proteins p21(ras)PyrimidinesKRAS protein, humanProtein Kinase InhibitorsMCL1 protein, human

Autor:innen und Institutionen

  • Division of Collaborative Research and Developments, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan; Division of Translational Genomics, Exploratory Oncology Research & Cli…
  • Division of Translational Genomics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan; Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, Na…
  • Division of Translational Genomics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
  • Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.

Zitieren

APA

Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., Shinno, Y., Yoshida, T., Horinouchi, H., Ohe, Y., Watanabe, S. I., Yatabe, Y., Kitai, H., Konno, S., Kobayashi, S. S., & Ohashi, A. (2025). WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217414

Vancouver

Yamamoto G, Tanaka K, Kamata R, Saito H, Yamamori-Morita T, Nakao T, et al. WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217414

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Gaku and Tanaka, Kosuke and Kamata, Ryo and Saito, Hitoshi and Yamamori-Morita, Tomoko and Nakao, Takehiro and Liu, Jie and Mori, Shunta and Yagishita, Shigehiro and Hamada, Akinobu and Shinno, Yuki and Yoshida, Tatsuya and Horinouchi, Hidehito and Ohe, Yuichiro and Watanabe, Shun-Ichi and Yatabe, Yasushi and Kitai, Hidenori and Konno, Satoshi and Kobayashi, Susumu S and Ohashi, Akihiro},
  title = {WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217414}
}
Kostenlos starten →